Healis Therapeutics Announces Supply Agreement with CKD Bio to develop CKDB-501 for neuropsychiatric indications NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation...

Fastox to present its long-lasting botulinum toxin LAST™ technology at the TOXINS 2022 6th International Conference. Press release Fastox to present its long-lasting botulinum toxin LAST™ technology at the TOXINS 2022 6th International Conference. Lausanne, July 5th, 2022 – Swiss biotech Fastox Pharma will...